PUBLISHER: 360iResearch | PRODUCT CODE: 1466438
PUBLISHER: 360iResearch | PRODUCT CODE: 1466438
Cryptococcosis Market by Treatment (Amphotericin B, Fluconazole, Flucytosine), Distribution Channel (Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2024-2030
[183 Pages Report] The Cryptococcosis Market size was estimated at USD 5.91 billion in 2023 and expected to reach USD 6.35 billion in 2024, at a CAGR 7.64% to reach USD 9.90 billion by 2030.
The Cryptococcosis market encompasses a range of pharmaceutical products, services, and activities involved in the prevention, diagnosis, treatment, and management of Cryptococcosis. It includes the sales of antifungal drugs specifically used to treat Cryptococcosis, a fungal infection caused by Cryptococcus species, which primarily affects the lungs and central nervous system. The primary applications of the Cryptococcosis market involve pharmaceutical therapies and diagnostic testing. An increasing rate of HIV/AIDS and other conditions leading to compromised immune systems contribute significantly to generating need for the Cryptococcosis medication. Advancements in diagnostic technologies allow for early and precise identification of the infection, thus propelling the demand for treatments. Expansion in healthcare infrastructure globally, especially in the developing countries, also foster's market growth. Potential opportunities exist in the untapped markets of emerging economies and in the further development of antifungal resistance management and personalized medicine approaches. Despite the growth factors, high costs associated with antifungal therapy can limit accessibility for some patients; there is also a growing concern over antifungal resistance which reduces the efficacy of existing treatments. Furthermore, poor healthcare infrastructure in some regions can impede the adoption of advanced therapeutics and diagnostics. Regulatory hurdles for drug approval and the limited pipeline of novel antifungal compounds also affect market potential. Advances in novel drug delivery systems, such as nanoparticle and targeted drug delivery, could greatly improve the efficacy of existing treatments. Research into alternative treatments, such as immunotherapies or combination therapies, could also offer breakthroughs in the management of the disease. Lastly, the development of rapid, sensitive, and cost-effective diagnostic tests is essential for early detection and treatment.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 5.91 billion |
| Estimated Year [2024] | USD 6.35 billion |
| Forecast Year [2030] | USD 9.90 billion |
| CAGR (%) | 7.64% |
Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis
Amphotericin B is a powerful antifungal medication often used as a primary treatment for severe cases of cryptococcosis, particularly cryptococcal meningitis. It is typically administered intravenously due to its poor oral bioavailability. Amphotericin B binds to ergosterol, a key component of fungal cell membranes, creating pores that lead to the cell's death. However, its use can be limited by significant side effects including nephrotoxicity (kidney damage), fever, chills, and anemia, therefore, monitoring is necessary during treatment. Fluconazole is a triazole antifungal medication used as a treatment for various forms of cryptococcal infections and as maintenance therapy to prevent recurrence of the disease. It is an advantageous treatment option due to its oral administration and favorable safety profile. Fluconazole works by inhibiting the fungal cytochrome P450 enzyme lanosterol 14-a-demethylase, which is required for the synthesis of ergosterol, thus disrupting fungal cell membrane synthesis. Despite its effectiveness, fluconazole resistance can occur, especially with prolonged use. Flucytosine, also known as 5-fluorocytosine, is an antifungal medication that is often used in combination with Amphotericin B for the treatment of cryptococcosis due to its synergistic effects. The drug is converted within fungal cells into 5-fluorouracil, which inhibits DNA and RNA synthesis, leading to cell death. Flucytosine is generally well-tolerated but can have side effects such as bone marrow suppression and gastrointestinal upset. Resistance to flucytosine can develop, and thus its use is typically reserved for combination therapy under careful medical supervision.
Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications
Cryptococcosis medications are distributed through various channels to ensure availability for patients. Hospital pharmacies represent a principal distribution channel for cryptococcosis medications. Hospitalized patients often receive their initial treatment in this setting, particularly if the infection is severe. Hospital pharmacies maintain a supply of crucial antifungals such as Amphotericin B and Flucytosine and ensure timely administration as part of inpatient care. These facilities are essential for acute management and for initiating treatment regimens that may be continued on an outpatient basis. Mail order pharmacies offer a convenient and often cost-saving avenue for patients managing cryptococcosis post-discharge or for those under long-term treatment plans. This distribution channel is beneficial for patients requiring consistent medication supplies with the added convenience of home delivery. Mail order services can be particularly advantageous for those living in remote areas or for patients with limited mobility. Retail pharmacies and drug stores serve as an accessible point of purchase for outpatient cryptococcosis medications. These establishments are crucial for patients who may need to fill or refill prescriptions rapidly, offering widespread geographic coverage and extended operating hours. Retail pharmacies also provide pharmaceutical care and counsel, playing a significant role in the overall management of the condition.
Regional Insights
In the Americas, particularly in the United States and Canada, cryptococcosis is considered an opportunistic infection predominantly affecting immunocompromised individuals, such as those with HIV/AIDS. Large-scale antiretroviral treatment programs have helped reduce the incidence of cryptococcosis, but it remains a concern. Customer purchasing behavior in these nations tends to prioritize well-established, FDA-approved treatments with a proven track record of efficacy. There has been an increase in investment towards research grants for studying cryptococcal meningitis, as well as a focus on improved diagnostic techniques. In EU countries, the consumer need for cryptococcosis treatments is largely driven by cases among immunocompromised patient populations. The EU follows stringent regulatory guidelines which influence purchasing behavior, often favoring products that have demonstrated not only efficacy but also cost-effectiveness. Recent EU initiatives, such as the Innovative Medicines Initiative, have supported research into new treatments. The MEA region exhibits a wide disparity in the incidence of cryptococcosis, with Sub-Saharan Africa bearing a significant burden due to high rates of HIV/AIDS. There is a clear need for affordable and accessible treatments within African markets, while wealthier Middle Eastern nations may focus on newer and more advanced therapy options. Public health initiatives aimed at HIV/AIDS in Africa also play a crucial role in the management of cryptococcosis. In the Asia Pacific, countries such as China, Japan, and India present diverse market dynamics. The Asia Pacific region is also seeing an uptick in patents related to antifungal medications, driven by local pharmaceutical companies seeking to address the regional needs.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cryptococcosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cryptococcosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cryptococcosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., B.M. Pharmaceuticals, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Citron Pharma, Eisai Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Jolly Limited, Lunan Pharmaceutical Group, Matinas Biopharma Holdings, Inc., Merck & Co., Inc., Novartis AG, NuCare Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Sigmapharm Laboratories, LLC, Skyepharma Production SAS, Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..
Market Segmentation & Coverage
This research report categorizes the Cryptococcosis Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Treatment
- Amphotericin B
- Fluconazole
- Flucytosine
- Distribution Channel
- Hospital Pharmacies
- Mail Order Pharmacies
- Retail Pharmacies & Drug Stores
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Americas
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Cryptococcosis Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cryptococcosis Market?
3. What are the technology trends and regulatory frameworks in the Cryptococcosis Market?
4. What is the market share of the leading vendors in the Cryptococcosis Market?
5. Which modes and strategic moves are suitable for entering the Cryptococcosis Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing Prevalence of Infectious Diseases and Fatal Fungal Disease
- 5.1.1.2. Rising Insights into HIV/AIDS-Associated Cryptococcosis
- 5.1.1.3. Increasing Availability of Generic and Over-the-Counter Medicine
- 5.1.2. Restraints
- 5.1.2.1. Limited Clinical Awareness in Patients Regarding Treatments
- 5.1.2.2. Reduced Scope of Testing and Diagnostics due to Increased Mortality Among Cryptococcosis Infected Patients
- 5.1.3. Opportunities
- 5.1.3.1. Favorable Government Programs for the Development of Effective Therapeutics for Cryptococcal Meningitis Disease
- 5.1.3.2. Increasing Drug Development and Evolving Clinical Trial Ecosystem for Cryptococcosis
- 5.1.4. Challenges
- 5.1.4.1. Side Effects Associated with The Usage of Cryptococcosis Drugs
- 5.1.4.2. Pharmaceutical Companies Failing to Address The Need and Poorly Funded Drug Development Programs
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.2.1. Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis
- 5.2.2. Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 5.9. Client Customization
6. Cryptococcosis Market, by Treatment
- 6.1. Introduction
- 6.2. Amphotericin B
- 6.3. Fluconazole
- 6.4. Flucytosine
7. Cryptococcosis Market, by Distribution Channel
- 7.1. Introduction
- 7.2. Hospital Pharmacies
- 7.3. Mail Order Pharmacies
- 7.4. Retail Pharmacies & Drug Stores
8. Americas Cryptococcosis Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
9. Asia-Pacific Cryptococcosis Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
10. Europe, Middle East & Africa Cryptococcosis Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
11. Competitive Landscape
- 11.1. Market Share Analysis, 2023
- 11.2. FPNV Positioning Matrix, 2023
- 11.3. Competitive Scenario Analysis
- 11.3.1. Astellas Completes Acquisition of Propella Therapeutics
- 11.3.2. Novartis Builds on Neuroscience Pipeline and xRNA Platform Capabilities with Acquisition of DTx Pharma
- 11.3.3. GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company BELLUS Health
12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.2. Key Product Portfolio
LIST OF FIGURES
- FIGURE 1. CRYPTOCOCCOSIS MARKET RESEARCH PROCESS
- FIGURE 2. CRYPTOCOCCOSIS MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. CRYPTOCOCCOSIS MARKET DYNAMICS
- FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 20. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. CRYPTOCOCCOSIS MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2023 (USD MILLION)
- TABLE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2024-2030 (USD MILLION)
- TABLE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
- TABLE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
- TABLE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2023 (USD MILLION)
- TABLE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2024-2030 (USD MILLION)
- TABLE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2023 (USD MILLION)
- TABLE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2024-2030 (USD MILLION)
- TABLE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2023 (USD MILLION)
- TABLE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2024-2030 (USD MILLION)
- TABLE 15. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 16. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 17. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
- TABLE 18. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
- TABLE 19. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
- TABLE 20. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
- TABLE 21. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2023 (USD MILLION)
- TABLE 22. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2024-2030 (USD MILLION)
- TABLE 23. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 24. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 25. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 26. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 27. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
- TABLE 28. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
- TABLE 29. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 30. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 31. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 32. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 33. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 34. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 35. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 36. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 37. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 38. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 39. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 40. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 41. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 42. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 43. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 44. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 45. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 46. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 47. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 48. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 49. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
- TABLE 50. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
- TABLE 51. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 52. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 53. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 54. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 55. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
- TABLE 56. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
- TABLE 57. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 58. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 59. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 60. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 61. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 62. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 63. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 64. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 65. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 66. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 67. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 68. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 69. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 70. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 71. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 72. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 73. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 74. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 75. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 76. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 77. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 78. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 79. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 80. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 81. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 82. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 83. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 84. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 85. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 86. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 87. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 88. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 89. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 90. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 91. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 92. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 93. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 94. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 95. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 96. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 97. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 98. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 99. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 100. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 101. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 102. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 103. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 104. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 105. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 106. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 107. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 108. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 109. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
- TABLE 110. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
- TABLE 111. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 112. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 113. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 114. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 115. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 116. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 117. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 118. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 119. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 120. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 121. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 122. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 123. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 124. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 125. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 126. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 127. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 128. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 129. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 130. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 131. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 132. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 133. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 134. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 135. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 136. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 137. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 138. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 139. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 140. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 141. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 142. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 143. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 144. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 145. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 146. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 147. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 148. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 149. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 150. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 151. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 152. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 153. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 154. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 155. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 156. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 157. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 158. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 159. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 160. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 161. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 162. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 163. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 164. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 165. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 166. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 167. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 168. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 169. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 170. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 171. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 172. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 173. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 174. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 175. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 176. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 177. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 178. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 179. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 180. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 181. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 182. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 183. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 184. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 185. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 186. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 187. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 188. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 189. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 190. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 191. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
- TABLE 192. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
- TABLE 193. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
- TABLE 194. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
- TABLE 195. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 196. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023
